At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Boston based CFO’ operating in the Biopharma space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
David Socks
Co-founder, CFO, and CBO of HilleVax
Follow David Socks:
About HilleVax, Phathom Pharmaceuticals: HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Diane Marcou
Consulting CFO of Satellite Bio
Ms. Marcou has provided financial and strategic advisory services to a number of venture-backed technology companies, including ByAllAccounts, Inc., Fluidnet Corporation, Radianse and T2 Biosystems. Prior to working as an independent financial consultant, she was Chief Financial Officer and Vice President of Finance and Administration for Incentive Systems (dba Centive), a privately held venture-funded software company, and Chief Financial Officer at Workgroup Technologies, a publicly traded software company with domestic and international operations. Ms. Marcou earned a B.S. in Business Administration from Boston College, and her CPA from PricewaterhouseCoopers, formerly Coopers & Lybrand.
Follow Diane Marcou:
About Boston MicroFluidics, Cytrellis Biosystems, Incentive Systems, Satellite Bio, Workgroup Technology: Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering.
Jeffrey Poulton
Chief Financial Officer of Shire
Jeffrey “Jeff” brings to the Board his financial, commercial and strategic acumen. Since joining Shire in 2003 he has held leadership positions in finance supporting the Neuroscience, Gastrointestinal and Rare Diseases business units as well as the positions of Interim Chief Financial Officer and Head of Investor Relations. In addition, Jeff oversaw the operations of the Rare Diseases business unit in North America, Latin America and Asia Pacific, as well as leading the integration of the legacy-Viropharma rare disease products into the Shire portfolio. Prior to joining Shire, Jeff spent time at Cinergy Corp. and PPG Industries in a variety of corporate finance and business development roles, in addition to serving as a commissioned officer in the U.S. Navy. He received a Bachelor of Arts in Economics from Duke University and a Master of Business Administration in Finance from the Kelly School of Business at Indiana University.
Follow Jeffrey Poulton:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Kam Unninayar
CFO of Tetraphase Pharmaceuticals
Follow Kam Unninayar:
About Tetraphase Pharmaceuticals: Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.
Howard Liang
President and CFO of Tessera Therapeutics
Follow Howard Liang:
About Tessera Therapeutics: Tessera Therapeutics is an early-stage life sciences company.
Marc Schneebaum
Chief Financial Officer of Avalyn Pharma
Follow Marc Schneebaum:
About Avalyn Pharma: Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis.
Ted Myles
Executive Vice President and Chief Financial Officer of AMAG Pharmaceuticals
Ted Myles joined ACT in June 2013, as the company’s Chief Financial Officer and Executive Vice President of Corporate Development. From November 2008 to June 2013 Ted Myles was with PrimeraDx, a privately-held molecular diagnostics company, where he served as Chief Financial Officer and Vice President of Operations. At PrimeraDx, Ted Myles helped to lead the company from the proof-of-concept stage to become a fully integrated commercial organization. Prior to joining PrimeraDx, Ted Myles was the Chief Financial Officer and Senior Vice President of Finance at Pressure BioSciences, a Nasdaq-listed, life-science tools company. Earlier in his career, Ted Myles held financial positions of increasing responsibility with EMD Pharmaceuticals (a subsidiary of Merck KGaA), SG Cowen Securities Corporation, Boston Biomedica and PriceWaterhouseCoopers. He received a master’s degree in business administration, with an emphasis on strategy and corporate finance, from Washington University in St. Louis and a bachelor’s degree in business administration from the University of Hartford. Ted Myles became a CPA in 1996.
Follow Ted Myles:
About AMAG Pharmaceuticals: AMAG Pharmaceuticals is a biopharmaceutical company, which utilizes the technology for the development and commercialization of therapeutic.
Ola Soderquist
CFO/Controller & Co-founder of Oxygen Therapy
Follow Ola Soderquist:
About Oxygen Therapy: Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.